GB0203527D0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
GB0203527D0
GB0203527D0 GB0203527A GB0203527A GB0203527D0 GB 0203527 D0 GB0203527 D0 GB 0203527D0 GB 0203527 A GB0203527 A GB 0203527A GB 0203527 A GB0203527 A GB 0203527A GB 0203527 D0 GB0203527 D0 GB 0203527D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0203527A
Other versions
GB2380129B (en
GB2380129A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0103638A external-priority patent/GB0103638D0/en
Priority claimed from US09/827,158 external-priority patent/US6730330B2/en
Priority claimed from GB0111597A external-priority patent/GB2377633A/en
Priority claimed from GB0121715A external-priority patent/GB2381194A/en
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of GB0203527D0 publication Critical patent/GB0203527D0/en
Publication of GB2380129A publication Critical patent/GB2380129A/en
Application granted granted Critical
Publication of GB2380129B publication Critical patent/GB2380129B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
GB0203527A 2001-02-14 2002-02-14 Pharmaceutical formulations Expired - Lifetime GB2380129B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0103638A GB0103638D0 (en) 2001-02-14 2001-02-14 Pharmaceutical formulations
US28004401P 2001-03-30 2001-03-30
US09/827,158 US6730330B2 (en) 2001-02-14 2001-04-05 Pharmaceutical formulations
GB0111597A GB2377633A (en) 2001-05-11 2001-05-11 Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB0121715A GB2381194A (en) 2001-09-07 2001-09-07 Pharmaceutical formulations
US59102201A 2001-09-12 2001-09-12

Publications (3)

Publication Number Publication Date
GB0203527D0 true GB0203527D0 (en) 2002-04-03
GB2380129A GB2380129A (en) 2003-04-02
GB2380129B GB2380129B (en) 2004-08-11

Family

ID=27546616

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0203527A Expired - Lifetime GB2380129B (en) 2001-02-14 2002-02-14 Pharmaceutical formulations

Country Status (1)

Country Link
GB (1) GB2380129B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US20220000763A1 (en) * 2018-11-07 2022-01-06 Columbia Care Llc Sublingual and buccal dosage forms of cannabinoid extracts and method of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US5192802A (en) * 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system

Also Published As

Publication number Publication date
GB2380129B (en) 2004-08-11
GB2380129A (en) 2003-04-02

Similar Documents

Publication Publication Date Title
GB0319041D0 (en) Pharmaceutical Formulations
IL156716A0 (en) Pharmaceutical formulation
IL164519A0 (en) Pharmaceutical formulations
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
GB0111597D0 (en) Pharmaceutical compositions
GB0118689D0 (en) Pharmaceutical formulation
GB0104534D0 (en) Pharmaceutical combination
PL366432A1 (en) Pharmaceutical formulation
GB2392093B (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
GB0124523D0 (en) Pharmaceutical combination
GB0104752D0 (en) Pharmaceutical compositions
GB0129270D0 (en) Pharmaceutical combination
GB0129397D0 (en) Pharmaceutical combination
GB2382302B (en) Pharmaceutical compositions
GB0124455D0 (en) Pharmaceutical formulations
GB0129395D0 (en) Pharmaceutical combination
GB0104749D0 (en) Pharmaceutical formulation
GB0115893D0 (en) Formulations
GB0101966D0 (en) Pharmaceutical formulations
GB0118299D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20220213